Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Laquinimod in multiple sclerosis.
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
UW-SES: A new self-efficacy scale for people with disabilities.
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
Amiloride HCl
Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Multiple Sclerosis: Vitamin D and calcium as environmental determinants of prevalence (A Viewpoint)
An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients.
Neuromyelitis optica.
Immunology 2012
Activities of daily living: evaluation and treatment in persons with multiple sclerosis.
Materials for stem cell factories of the future.

Pages